Drugs / RPT904
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07220811 Comparator | Oct 2025 → Apr 2027 expected | food allergy | RAPT Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPT904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220811 ↗ |
| Action | Inhibit | “anti-IgE” NCT07220811 ↗ |
| Modality | Monoclonal antibody | “RPT904, a next-generation anti-IgE monoclonal antibody” NCT07220811 ↗ |
| Route | Subcutaneous | “RPT904 subcutaneous injection every 8 weeks” NCT07220811 ↗ |